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§Department of Orthopaedic Surgery, University of California, San Francisco, CaliforniaABSTRACT It was recently demonstrated that mechanical shearing of synovial fluid (SF), induced during joint motion, rapidly
activates latent transforming growth factor b (TGF-b). This discovery raised the possibility of a physiological process consisting
of latent TGF-b supply to SF, activation via shearing, and transport of TGF-b into the cartilage matrix. Therefore, the two primary
objectives of this investigation were to characterize the secretion rate of latent TGF-b into SF, and the transport of active TGF-b
across the articular surface and into the cartilage layer. Experiments on tissue explants demonstrate that high levels of latent
TGF-b1 are secreted from both the synovium and all three articular cartilage zones (superficial, middle, and deep), suggesting
that these tissues are capable of continuously replenishing latent TGF-b to SF. Furthermore, upon exposure of cartilage to active
TGF-b1, the peptide accumulates in the superficial zone (SZ) due to the presence of an overwhelming concentration of nonspe-
cific TGF-b binding sites in the extracellular matrix. Although this response leads to high levels of active TGF-b in the SZ, the
active peptide is unable to penetrate deeper into the middle and deep zones of cartilage. These results provide strong evidence
for a sequential physiologic mechanism through which SZ chondrocytes gain access to active TGF-b: the synovium and articular
cartilage secrete latent TGF-b into the SF and, upon activation, TGF-b transports back into the cartilage layer, binding exclu-
sively to the SZ.INTRODUCTIONTransforming growth factor b (TGF-b) is a multifunctional
cytokine that modulates the differentiation, proliferation,
and extracellular matrix (ECM) production of various bio-
logical tissues (1). Traditionally, investigators have been
particularly interested in TGF-b’s role in the development
and maintenance of articular cartilage due to its high native
levels in synovial joints (2,3) and its well-characterized
ability to modulate the biosynthesis of a large number of
cartilage ECM products (4–8). However, efforts to elucidate
TGF-b’s native role in the tissue have focused primarily on
ex situ experimental models that exclusively describe the
downstream effects of TGF-b on chondrocytes. These
studies typically did not address a host of TGF-b events
that occur in the tissue ECM, such as TGF-b activation
and binding interactions. As a result, the extracellular regu-
lation of TGF-b activity and the physiologic mechanisms
through which chondrocytes access the growth factor
remain unclear.
In cartilage, as in other tissues, TGF-b is synthesized in
an inactive latent complex that is unable to bind to cellular
membrane receptors, and thus initially unable to induce
a biological response (9). In this latent complex, the
25 kDa mature TGF-b peptide is linked noncovalently to
a 70 kDa latency-associated peptide (LAP), and together
they form the small latent complex (SLC). This complexSubmitted September 20, 2012, and accepted for publication February 19,
2013.
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0006-3495/13/04/1794/11 $2.00may be disulfide-bonded to a latent TGF-b binding protein
(LTBP, ~180 kDa), constituting a configuration termed the
large latent complex (LLC). Although latent TGF-b is
present in synovial fluid (SF) at relatively high concentra-
tions (10–40 ng/mL (10–12)), the mature peptide must first
undergo activation (release from LAP) before it can modu-
late the metabolic activity of cartilage.
Mechanisms behind the activation of latent TGF-b in
healthy SF have not been addressed extensively in the
literature. In a recent experimental investigation, we
demonstrated that mechanical shearing of SF can serve
as a critical mediator of latent TGF-b activation (13).
During joint motion, opposing articular surfaces slide rela-
tive to one another, producing high levels of fluid shear in
the SF. The shearing produced during physiologic levels
of joint motion rapidly activates a large fraction of the
latent TGF-b that is present, which remains stable in SF
for at least several hours. Furthermore, TGF-b activation
does not occur spontaneously in the absence of shearing,
which strongly suggests that mechanical shearing forces
(as opposed to chemical mediators) serve as the dominant
mechanism of TGF-b activation in healthy SF.
Considering the well-established effect of active TGF-b
on chondrocyte biosynthesis, shear-induced activation of
latent TGF-b is likely to have a strong influence on the
metabolic activity of articular cartilage. However, the phys-
iologic role that this mechanism plays in the complex native
environment of the synovial joint remains unclear. The
metabolic impact of this mechanism requires a continuoushttp://dx.doi.org/10.1016/j.bpj.2013.02.052
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TGF-b to act on surrounding cells.
Physiologic levels of SF shearing can rapidly activate
latent TGF-b at a rate of ~0.5 ng/mL per hour (13). There-
fore, the level of active TGF-b in the joint may heavily
depend on the rate at which latent TGF-b is secreted and re-
plenished into SF. In previous studies, TGF-b was shown to
undergo synthesis from synoviocytes (14) and chondrocytes
(2,3,15–18). These studies were primarily conducted on iso-
lated cells or for short culture durations. Therefore, the rate
at which latent TGF-b is secreted in situ remains unclear.
In principle, upon activation, the mature TGF-b peptide is
free to diffuse from SF into the adjoining articular cartilage
ECM. However, in most tissues, TGF-b is believed to act
locally in an autocrine or paracrine fashion, in the imme-
diate proximity of its region of activation (19). Therefore,
the transport of active TGF-b through a dense ECM has
not been previously characterized. Evidence suggests that
this transport may be a complex process due to extracellular
interactions with matrix proteins and cellular receptors.
Active TGF-b can bind to a large variety of molecules
present in the cartilage ECM, such as proteoglycans (20–
22), collagens (23,24), and glycoproteins (25,26). As
demonstrated previously for other growth factors (27), these
binding interactions can potentially influence the transport
rate and spatial distribution of active TGF-b in the tissue.
Based on this understanding, the primary goals of this
investigation were to: 1), characterize the rate of secretion
of latent TGF-b into SF; and 2), characterize the transport
of active TGF-b across the articular surface and into carti-
lage tissue.MATERIALS AND METHODS
To characterize the physiologic secretion of latent TGF-b into SF, we
measured its synthesis and secretion from explants of synovium and
different zones of articular cartilage into conditioned media (study 1). To
characterize the physiologic rate of transport of activated TGF-b from SF
into articular cartilage, we adopted an experimental transport system (study
2). Here, cartilage explants were exposed to a bath of 10 ng/mL exogenous
active TGF-b1 and its uptake across the articular surface was monitored
over time. We selected this exogenous concentration based on our earlier
shear-activation study, in which low physiologic levels of SF shearing acti-
vated the TGF-b1 isoform at a rate of 0.5 ng/mL/h (13). Considering that
additional isoforms (TGF-b2 and TGF-b3) are present in SF, the 10 ng/
mL exogenous bath concentration may be representative of activated levels
during a 1–2 day period of normal joint activity. Furthermore, to assess
whether TGF-b can transport from SF into articular cartilage before activa-
tion, we measured the uptake of commercially available SLC TGF-b1 in
explants. Lastly, to interpret and validate the experimental results of active
TGF-b uptake, we conducted a finite-element simulation to theoretically
assess the transport behavior (study 3).Materials
Cylindrical explants of articular cartilage (with an intact articular surface)
and sections of synovial tissue were obtained from the femoral condyles and
capsule of 2-month-old calf knee joints within 24 h of sacrifice. In total,nine joints were used in this investigation, with samples evenly distributed
from three joints for each study. For tissue culture experiments, samples
were maintained sterilely in an ITS-media formulation consisting of Dul-
becco’s modified Eagle’s medium (DMEM), insulin-transferrin-selenous
acid (1% ITSþ Premix), 50 mg/mL L-proline, 1% antibiotic-antimycotic
(100 U/mL penicillin, 100 mg/mL streptomycin, and 0.25 mg/mL amphoter-
icin-B), 0.1 mM dexamethasone, 10 mg/mL sodium pyruvate, and 50 mg/mL
ascorbate-2-phosphate. For experiments with devitalized tissue, samples
were frozen and stored at 30C for 1–2 weeks until testing. Active
TGF-b1, active TGF-b3, and latent TGF-b1 (SLC) were supplied in human
recombinant form from R&D Systems. Experiments were conducted in
untreated polystyrene well plates and tissue/solution samples were
collected in silanized polypropylene Eppendorf tubes. In all experiments
(for both live and devitalized tissue), growth factors were reconstituted in
the ITS media. The use of this media reconstitution was found to prevent
the often-problematic occurrence of active TGF-b binding to the aforemen-
tioned plasticware (28).TGF-b measurement
For all experiments (studies 2 and 3), at the completion of testing, cartilage
explants were weighed, minced, and treated with a solution of 4 M guani-
dine hydrochloride, supplemented with protease inhibitors, at 4C for
2 days to extract their TGF-b content, as reported previously (2). TGF-b1
concentrations were determined through an enzyme-linked immunosorbent
assay (ELISA) kit specific for TGF-b1 (R&D Systems) using recombinant
human active TGF-b1 as standards. This kit specifically detects the TGF-b1
isoform (human and bovine), but only recognizes it in the active form.
Therefore, for TGF-b synthesis testing, conditioned media samples were
assayed before and after an acid activation treatment (acidification for
15 min with 20% of 1 N HCl, followed by neutralization with an equal
volume of 1.2 N NaOH/0.5 M HEPES), allowing for independent measures
of their active and total (active þ latent) TGF-b1 content. In explants,
guanidine hydrochloride treatment activates and extracts all TGF-b from
the tissue. Therefore, measures in explants represent their total (endogenous
bovine þ exogenous human recombinant) TGF-b1 content. TGF-b1
concentrations are expressed based on the fluid volume of the explant
(given an experimentally determined sample water content: wet weight
fraction of 0.87 5 0.02). Guanidine extracts were diluted at least 20-fold
in ITS-DMEM before assays were performed. A separate test confirmed
that assay measurements were not affected by the presence of ECM constit-
uents in guanidine extracts (see Supporting Material).
For the latent TGF-b1 uptake experiment (study 2), concentrations of the
TGF-b1 SLC in explants and the external bath were determined through an
ELISA for LAP with recombinant human LAP as standards. Mouse mono-
clonal IgG antibodies (R&D Systems) were used for capture (clone #9005,
2 mg/mL) and detection (clone #27240, 4 mg/mL). All other reagents were
implemented as recommended in the TGF-b1 Duoset kit. This assay is
specific for human LAP and therefore detects only exogenous human
SLC while ignoring endogenous levels in bovine samples.Study 1: TGF-b synthesis rate from cartilage
and synovium explants
Live cylindrical cartilage explants (B3 0.5 mm) from the superficial zone
(SZ; 0 mm below the articular surface), middle zone (0.5 mm below
surface), and deep zone (1.5 mm below surface), and patches of synovial
tissue (z5 mg) were individually cultured in ITS media (300 mL per
sample, n ¼ 5 per tissue type) for up to 8 days. Further, to examine the
autoinduction of TGF-b synthesis, an additional set of SZ explants were
individually cultured in ITS media with varying levels of exogenous active
TGF-b3 (0, 1 ng/mL, or 10 ng/mL). TGF-b3 was used here to distinguish
between exogenous and endogenous TGF-b content, since assays only
detect TGF-b1. The media were changed daily. Conditioned media wereBiophysical Journal 104(8) 1794–1804
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released from each explant and expressed as the concentration based on
the volume of the explant (approximated from mass measurements). At
the end of the culture period, all live cartilage and synovial tissue explants
were digested in 0.5 mg/mL Proteinase-K (MP Biomedicals) in 50 mM
Tris-buffered saline containing 1 mM ethylenediaminetetraacetic acid,
1 mM iodoacetamide, and 10 mg/mL pepstatin A, at 56C for 16 h. The
DNA content of digested samples was quantified with the PicoGreen assay
(Invitrogen), as described previously for cartilage (29), with bacteriophage
lDNA standards. Furthermore, the endogenous TGF-b1 content of an addi-
tional set of SZ explants was determined before and after a 12 day culture
period (n ¼ 6 for each).Study 2: Experimental rate of penetration of
TGF-b1 into articular cartilage
Active TGF-b1
Cylindrical devitalized cartilage explants (B4 2.5 mm) were inserted into
thin sections of Tygon tubing (4 mm inner diameter, 3 mm long) and fixed
to the bottom of a polystyrene dish with cyanoacrylate glue. This configu-
ration laterally confines each explant, ensuring that solute transport occurs
only in one dimension across the solution-exposed articular surface. The
absence of fluid leakage between the tubing and explant lateral surface
was confirmed with the use of a fluorescent dye (results not shown).
Samples were exposed to 10 ng/mL exogenous active TGF-b1 in ITS media
(10 mL per sample) and after 0.5, 20, and 40 h the bath samples and
explants were removed and frozen (n ¼ 6 per time point). The frozen
explants were sectioned with a freezing stage sledge microtome into
160 mm slices from the solution-exposed articular surface (up to 800 mm
deep). The slices were then processed for their TGF-b1 content to measure
the concentration at discrete positions through the depth of the tissue.
Because the aforementioned TGF-b1 ELISA detects both bovine and
human recombinant TGF-b1, both endogenous and exogenous TGF-b1
are detected through this analysis. Therefore, control samples exposed to
TGF-b-free ITS DMEM were utilized to independently assess endogenous
TGF-b1 levels through the depth of the tissue after 0.5 and 40 h (n ¼ 6 per
time point). All experiments were performed on an orbital shaker at 22C.
Latent TGF-b1
Cylindrical devitalized cartilage explants (B3  0.5 mm) were exposed to
a bath of exogenous latent TGF-b1 (SLC) at 100 ng/mL or 1000 ng/mL
(n ¼ 6 per concentration). After 24 h, explants and bath samples were
collected, frozen, and processed for their exogenous SLC content.Study 3: Theoretical analysis of active TGF-b1
uptake into articular cartilage
To help interpret and validate our experimental uptake results, we per-
formed a finite-element (computational) simulation to theoretically predict
the rate of penetration of active TGF-b into articular cartilage. This simu-
lation required knowledge about the transport and binding properties of
active TGF-b in the cartilage ECM, i.e., the diffusivity, D; partition coeffi-
cient, k; the concentration of binding sites, Nt; and the dissociation constant,
KD. To characterize these parameters, we employed an experimental system
in which TGF-b levels were monitored in thin devitalized cartilage explants
that were exposed to a bath of exogenous active TGF-b. The following
sections describe the experimental and theoretical techniques implemented
for this characterization.
Theoretical model
The required TGF-b binding parameters can be independently determined
using a Langmuir model, where it is assumed that free active TGF-b canBiophysical Journal 104(8) 1794–1804reversibly bind to a finite number of uniformly distributed binding sites
in the ECM of cartilage:
½Active TGF-bfreeþ½Binding Sites%½Active TGF-bbound:
According to the law of mass action, under the assumption of elementary
reaction kinetics, the binding rate of free active TGF-b can be described bydCF
dt
¼ CB

kf CF þ kr
 kf NtCF; (1)
where CF and CB are the respective concentrations of free and bound active
TGF-b, Nt is the total concentration of binding sites in the tissue, and kf and
kr are the respective forward and reverse reaction rates.
When cartilage explants are exposed to a solution of exogenous active
TGF-b, due to steric volume effects and/or long-range electrostatic interac-
tions, active TGF-b is partially excluded from its interstitial pore space,
which limits its free concentration in the tissue. At equilibrium, this parti-
tioning can be described through the relation:
CF ¼ kCBath; (2)
where k is the partition coefficient of active TGF-b in the tissue and CBath is
its concentration in the bathing solution. From Eqs. 1 and 2, at equilibrium
(dCF/dt ¼ 0), the normalized TGF-b uptake ratio RU can be expressed as
RU ¼ CB þ CF
CBath
¼ k

1þ Nt
KD þ kCBath

; (3)
where KD ¼ kr/kf is the dissociation constant. This equation expresses
a sigmoidal relation between the free TGF-b concentration in the tissue,
CF or kCBath, and the TGF-b uptake ratio. When the free TGF-b concentra-
tion is much lower than the dissociation constant (CF  KD), RU
approaches the value k(Nt/KD þ 1). As CF approaches KD, the binding
sites begin to saturate and RU decreases in a sigmoidal fashion. Finally,
when CF [ KD, the available binding sites become saturated with
TGF-b, and RU approaches k.
Upon exposure of an active TGF-b bath solution to cartilage, the bath
concentration will decrease as free TGF-b binds to the tissue. Initially,
for a thin tissue section (where diffusion time into the tissue is negligible)
and when all binding sites are unoccupied (CB ¼ 0), from Eqs. 1 and 2, the
bath concentration can be approximated by
dCBath
dt
z kf NBathCBath; (4)
where NBath is the number of binding sites in the tissue normalized to the
volume of the bath. NBath can be multiplied by the ratio of tissue to bath
volume to recover Nt.
Equilibrium binding of TGF-b1
We formulated an experiment to determine the binding parameters Nt and
KD by measuring the bound TGF-b uptake ratio RU in explants at equilib-
rium and curve-fitting the data to Eq. 3. According to Eq. 3, to extract
a unique solution from the data, it is necessary to measure RU over a
wide range of TGF-b bath concentrations (including ranges where CFKD
and CF [ KD). Therefore, thin explant slices (B3  0.5 mm) were
exposed to a 10 mL bath of exogenous active TGF-b1 over the wide range
of 0, 5, 10, 20, 65, 95, or 450 ng/mL for 24 h (n¼ 6 per concentration). The
explant size was selected to ensure that active TGF-b1 would equilibrate
over the time course of the experiment (assumption of Eq. 3). The suit-
ability of the 24 h incubation period for achieving equilibrium was assessed
by additional exposure of slices to a 10 ng/mLTGF-b1 bath for 0, 0.5, 5, 24,
and 48 h. Experiments were conducted on an orbital shaker at 22C. After
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measure of their TGF-b1 content. The concentration of exogenous TGF-b1
in explants (CB þ CF) was determined by measuring the total explant
TGF-b1 content and subtracting the endogenous content as determined
from control explants. For all samples, the normalized uptake ratio RU
was determined and curve-fitted to Eq. 3.
Transient binding of TGF-b1
We formulated another experiment to determine the product Ntkf by
measuring the loss of the active TGF-b content of a bathing solution as
a result of its binding to the ECM of an immersed cartilage explant, and
then curve-fitting the data to Eq. 4. Thin explant slices (B4  0.16 mm,
n ¼ 5) were exposed to a 300 mL bath of 6.8 ng/mL exogenous active
TGF-b1. The tissue thickness was selected to minimize the diffusion
time of TGF-b1 into the tissue (since Eq. 4 assumes that diffusion time is
negligible). The bath volume was selected to yield a measurable decrease
in the bath TGF-b1 concentration during the experiment. Experiments
were also conducted on an orbital shaker at 22C. Initially and after 10,
30, 60, and 120 min of exposure, a small aliquot of the bath was acquired
and frozen for subsequent measurements of the decreasing concentration
of exogenous active free TGF-b1 in the explant. The initial rate of free
TGF-b1 loss, dCBath/dt, was determined and used to calculate the quantity
Ntkf through Eq. 4.
Finite-element analysis
The open-source finite-element program FEBio (www.febio.org) (30,31)
was used to model the one-dimensional (1D) transport of active TGF-b1
at 10 ng/mL from the articular surface into a cylindrical cartilage explant
(B4  2.5 mm). The code was extended to account for reversible binding
kinetics according to the relation of Eq. 1. The model employed the values
of Nt, KD, and kf obtained from the above experimental measurements. The
diffusivity D and partition coefficient k of the 25 kDa active TGF-b in carti-
lage were estimated at values of 21.3 mm2/s and 0.09, respectively, from the
interpolation of data from other proteins and polysaccharides in the tissue
(32). To account for the loss of active TGF-b in the bath as it accumulates
in the cartilage explant, the bathing solution was modeled with a finite
TGF-b content and with a volume of 10 mL as utilized in experiments.
The finite-element solution provided the spatiotemporal responses of free
(CF) and bound (CB) active TGF-b1 in the explant. For comparison
purposes, an additional simulation was conducted to examine the 1D uptake
of active TGF-b1 in the absence of binding interactions (Nt ¼ 0).Statistical analysis
A two-way analysis of variance (ANOVA, a ¼ 0.05) was performed to
determine the effect of TGF-b exposure and tissue depth on cartilage
TGF-b1 levels during the active TGF-b penetration test (study 2), with
statistical significance set at p < 0.05. One-way ANOVAs were performed
to detect differences in latent TGF-b1 synthesis rates between different0
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Btissue types and TGF-b3 supplementation levels (study 1), and in the uptake
ratio, RU, for different TGF-b bath concentrations in the equilibrium
binding test (study 3). Tukey’s post hoc test was used to detect differences
in the means. For comparison between SLC concentrations in explants at
the 100 ng/mL and 1000 ng/mL bath concentrations, an unpaired Student’s
t-test (two-tailed) was used.RESULTS
Study 1: TGF-b synthesis rate
The concentrations of TGF-b1 released by samples are re-
ported based on the volume of the explant rather than the
volume of the conditioned media. Cartilage explants
possessed high levels of endogenous TGF-b1 in their
ECM, and all tissues continued to synthesize and release
TGF-b1 throughout the culture period as described here.
All tissues exhibited constant TGF-b1 synthesis rates, as
illustrated by linear relationships in cumulative secretion
over time (mean R2 ¼ 0.99 5 0.01; Fig. 1 A). Active
TGF-b1 was not detected in the conditioned medium of
any samples, indicating that TGF-b1 was released predom-
inantly in the latent form. In the absence of exogenous
TGF-b, synovium and cartilage explants (all tissue zones)
released latent TGF-b1 at similar rates, whether considered
on the basis of explant volume or cell content (Table 1). The
supplementation of exogenous TGF-b3 significantly
increased the latent TGF-b1 synthesis rate (p < 0.001;
Fig. 1 B). No significant cell death was observed in these
samples as indicated by viability staining (results not shown).
Large concentrations of latent TGF-b1 were measured in
the ECM of SZ cartilage (82.75 11.6 ng/mL). These levels
did not change after 12 days of culture (75.15 21.1 ng/mL,
p ¼ 0.51). Further, devitalized cartilage explants released
near-zero levels of TGF-b1 into conditioned media
(0.34 5 0.17 ng/mL/day).Study 2: Experimental rate of penetration
of TGF-b1 into articular cartilage
Active TGF-b1
Endogenous levels of TGF-b1 varied throughout the depth
of devitalized explants, decreasing from 207 5 20 ng/mL1 10
ed active TGF- 3
ration (ng/mL)
*
*
FIGURE 1 (A) Cumulative secretion of latent
TGF-b1 from cultured synovium and middle-
zone cartilage tissue explants. The slope represents
the secretion rate from tissue (ng/mL/day on tissue
volume basis). (B) Secretion rate of latent TGF-b1
from SZ cartilage explants during exposure to
varying levels of exogenous active TGF-b3.
*p < 0.001 indicates significant increase above
control (0 ng/mL TGF-b3) secretion rate.
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TABLE 1 Secretion rate of latent TGF-b1 from explants of
synovium and different tissue zones (superficial, middle, and
deep) of articular cartilage
Latent TGF-b1 secretion rate
Per tissue volume
(ng/mL per day)
Per cell number
(ng/million cells per day)
Superficial zone 6.7 5 0.8 0.055 0.03
Middle zone 9.6 5 2.7 0.075 0.04
Deep zone 8.3 5 0.9 0.085 0.01
Synovium 6.7 5 1.9 0.045 0.03
1798 Albro et al.near the articular surface (80 mm deep) to 1185 41 ng/mL
at 880 mm deep (Fig. 2 A). At all positions throughout the
depth, endogenous levels remained unchanged after 40 h
of incubation (p ¼ 1.0). Upon exposure to exogenous active
TGF-b1, its concentration near the articular surface
increased significantly, reaching 556 5 283 ng/mL after
20 h (p< 0.001, relative to 40 h control; Fig. 2 B). However,
no significant increase above endogenous levels was de-
tected below 240 mm into the tissue (p > 0.99), indicating
that active TGF-b1 did not reach this depth even after
40 h of exposure. This 35-fold increase above the external
bath concentration (total levels minus endogenous levels,
divided by bath concentration) suggests that active
TGF-b1 binds substantially to the cartilage ECM.
Latent TGF-b1
After 24 h, the ratio of the SLC concentration in cartilage
explants, normalized to the bath concentration, was 0.045
0.01 (for 100 ng/mL bath), indicating that the SLC is
substantially partitioned from the tissue ECM. At the higher
SLC bath concentration (1000 ng/mL), the normalized ratio
did not change significantly (0.05 5 0.02, p ¼ 0.51).Study 3: Theoretical analysis of active TGF-b1
uptake into articular cartilage
Experiments
Transient binding of TGF-b1. The bath concentration of
free active TGF-b1 decreased monotonically, from 6.80 5
0.31 ng/mL to 4.86 5 0.17 ng/mL after 2 h (Fig. 3), due0
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Biophysical Journal 104(8) 1794–1804to binding with the cartilage explant. The initial slope, eval-
uated from the first two time points (0 and 10 min), was
calculated (dCbath/dt ¼ 3.05 ng/mL/h) and used with Eq.
4 to produce Ntkf z 1.8 min
1.
Equilibrium binding of TGF-b1. Measurement of the tran-
sient uptake of active TGF-b1 in cartilage explants
confirmed that the 24 h exposure period was indeed suffi-
cient to reach equilibrium in the tissue (Fig. 4 A). TGF-b1
levels in explants increased linearly with bath concentration
(R2 ¼ 0.94; Fig. 4 B) at a slope of 63.2, indicating that on
average the concentration was 63-fold higher in the tissue
relative to the surrounding bath. When it was normalized,
the uptake ratio averaged RU ¼ 57.3 5 14.3 for all groups
and exhibited no statistical decrease with increasing TGF-
b1 bath concentration (Fig. 5). According to Eq. 3, this
constant ratio is equal to the value k(Nt/KD þ 1). However,
the lack of a sigmoidal transition point in the data indicates
that even at the highest TGF-b1 bath concentration em-
ployed here (CBath ¼ 450 ng/mL), the binding sites did
not undergo saturation. Therefore, this experiment was
unable to yield definitive values for Nt or KD. According
to Eq. 3, the earliest this sigmoidal transition can occur is
immediately after a bath concentration of 450 ng/mL, as
indicated by the theoretical curve in Fig. 5 (case 1), for
which Nt ¼ 4  105 ng/mL (given k ¼ 0.09). Therefore,
the understanding that this transition will occur at or beyond
this point yields the constraint Nt R 4  105 ng/mL. To
examine the impact of this uncertainty, we implemented
three hypothetical binding cases in the finite-element simu-
lations, which examine parametric variations in Nt. These
cases consisted of further delayed saturation transition
points (Fig. 5) corresponding to Nt ¼ 4  105 (case 1),
40 105 (case 2), or 400 105 (case 3) ng/mL. The remain-
ing governing binding parameters were computed based on
the experimentally determined constraints, Nt/KD ¼ 636
(given RU ¼ 57.3 and k ¼ 0.09) and Ntkf ¼ 1.8 min1,
and are summarized in Table 2.
Finite-element analysis
Theoretical predictions of the 1D (through-the-depth)
uptake of active TGF-b1, based on the experimentally deter-
mined binding parameters (Table 2), were generated and00 600 800
pth (µm)
 40 hour
 20 hour
 0.5 hour
 TGF-  exposed
FIGURE 2 1D uptake of active TGF-b1 into
articular cartilage. (A) Depth-dependent variation
of endogenous levels of latent TGF-b1 in cartilage
explants after incubation in TGF-b-free solution.
(B) Depth-dependent levels of TGF-b1 (endoge-
nous latent þ exogenous active) after exposure of
the articular surface to a bath of 10 ng/mL active
exogenous TGF-b1. *p < 0.001 indicates signifi-
cant increase above corresponding endogenous
levels. Both 20 and 40 h uptake values were
compared with 40 h endogenous control.
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FIGURE 3 Transient decrease of the exogenous active TGF-b1 concen-
tration in a bathing solution due to TGF-b1 binding to the ECM of
a submerged cartilage explant. The dashed line represents the initial slope,
which was used to determine the product Ntkf according to Eq. 4.
TGF-b Accumulation in Superficial Cartilage 1799plotted for multiple time points (Fig. 6 A). For consistency
with the presentation of experimental results in Fig. 2 B,
theoretically predicted active TGF-b1 concentrations in
the tissue were superposed over the (smoothed) experi-
mentally measured endogenous levels (Fig. 2 A). The
theoretical uptake prediction for parametric case 1 (Nt ¼
4  105 ng/mL) may be compared with the experimentally
determined results (Fig. 2 B). Predictions show that the
concentration of active exogenous TGF-b1 at the articular
surface reaches levels 40-fold higher than the bath concen-
tration, consistent with experimental results. Furthermore,
predictions show that active exogenous TGF-b1 penetrates
very slowly into the tissue and is not present below 240
mm into the tissue even after 40 h of exposure, also in agree-
ment with experimental results. No significant differences
were observed in the theoretical predictions between any
of the three parametric cases for Nt, indicating that the
theoretical prediction was insensitive to the uncertainty in
this parameter for the given conditions (i.e., for Nt R 4 
105 ng/mL and testing durations % 40 h). Further simula-
tions demonstrate that this 800 mm thick section of tissue
will not equilibrate throughout its depth, even after 1 year
of exposure time. In contrast, simulations in the absence
of binding indicate that the concentration of active0.1
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ATGF-b1 should become nearly uniform throughout this
section after only 40 h, at a value equal to kCBath (Fig. 6 B).DISCUSSION
Traditionally, it has been understood that TGF-b plays an
important role in the development and maintenance of artic-
ular cartilage (4). However, few studies have addressed the
physiologic extracellular events that regulate chondrocyte
access to TGF-b in the tissue, including its secretion, activa-
tion, and binding to the ECM. The results of this study
advance two important concepts: 1), large amounts of latent
TGF-b1 are continuously synthesized and secreted from
both the synovium and articular cartilage; and 2), upon acti-
vation, TGF-b1 binds substantially to and accumulates in
the SZ of articular cartilage.
To our knowledge, this is the first study to explicitly
compare the rates of latent TGF-b1 secretion from articular
cartilage and synovium tissue explants. The elevated,
constant secretion rates demonstrated in this study (Fig. 1)
strongly suggest that these surrounding tissues of the syno-
vial joint are capable of supplying and continuously replen-
ishing a large amount of latent TGF-b1 to SF. The
demonstrations that: 1), endogenous TGF-b1 levels remain
constant in cartilage explants throughout the culture period;
and 2), TGF-b1 is not secreted from devitalized explants
indicate that tissues are in fact synthesizing latent TGF-b1
rather than releasing it from their matrix. Furthermore,
results indicate that all cartilage tissue zones contribute to
this supply, and that synthesis in cartilage is autoinduced
by active TGF-b, as observed in isolated chondrocytes
(16) and other tissues (33–36). Considering the typical
volume of SF (5 mL (37)) and cartilage tissue (20 mL
(38)) in a human knee joint, these results suggest that on
the order of 40 ng/mL of latent TGF-b1 is supplied to the
SF per day.
Although it is well understood that TGF-b can bind to
a large variety of ECM constituents, our results demonstrate
that these interactions can significantly influence the trans-
port of active TGF-b into articular cartilage, as evidenced
by the 35-fold concentration enhancement in the SZ and
substantially delayed penetration further into the tissue0.100 1.000
h concentration
3 ng/mL)
FIGURE 4 (A) Concentration of endogenous
and exogenous (boundþ free) TGF-b1 in cartilage
matrix after exposure to 10 ng/mL of exoge-
nous active TGF-b1 or a TGF-b1-free solution
(0 ng/mL) for up to 48 h. (B) Concentration of
exogenous (bound þ free) TGF-b1 in cartilage
matrix after exposure to varying levels of exoge-
nous active TGF-b1 (4–450 ng/mL) for 24 h.
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FIGURE 5 Normalized equilibrium uptake ratio, RU, of exogenous active
TGF-b1 in the cartilage matrix versus exposed bath concentration. Accord-
ing to Eq. 3, as the bath concentration approaches zero, this concentration
ratio is equal to the value k(Nt/KDþ 1). Dashed curves represent theoretical
cases of Eq. 3 based on parameters summarized in Table 2. Each curve
reflects a different binding site transition point. *p < 0.01 indicates signif-
icant increase above the value at the lowest TGF-b1 bath concentration.
1800 Albro et al.(Fig. 2). In contrast, according to Fick’s law of diffusion,
the concentration of a freely diffusing (nonbinding)
25 kDa molecule should not exceed the value of kCBath
(~1 ng/mL), and should reach a nearly uniform distribution
throughout the entire 800 mm depth of the explant after only
40 h (Fig. 6 B). The ability of the theoretical binding-
transport model to faithfully describe the actual response
(Fig. 6 A) confirms that these observations can be mostly
attributed to the nonspecific binding of active TGF-b1 to
the cartilage ECM, rather than to experimental artifacts or
a complex heterogeneous distribution of binding sites. It is
interesting to note that according to these measurements,
the extensive binding response is not due to a particularly
high affinity of TGF-b1 to binding sites. The dissociation
constant of active TGF-b1 in cartilage implemented in theo-
retical case 1 (KD¼ 25.2 nM) is greater than that of IGF-1 to
its specific binding protein (KD ¼5.1 nM (39)), indicating
a lower binding affinity. Rather, it results from the vast
concentration of binding sites in the tissue; the concen-
tration of binding sites Nt is at least 6 orders of magnitude
greater than the 10 ng/mL exogenous bath concentration.
From a physical perspective, as active TGF-b begins to
diffuse into the tissue, it must first occupy and fill an over-
whelming supply of binding sites before it progresses
further into the tissue. Even in the absence of cellular bio-
logical processes, it would take more than a year for theTABLE 2 Experimentally determined binding parameters implemen
Case # Nt/KD
Binding site
density, Nt
[  105 ng/mL]
Dissociation
constant, KD
[ 105 ng/mL]
Forwar
consta
[ 106 min
1 636 4 0.0063 4.6
2 636 40 0.063 0.4
3 636 400 0.63 0.04
Biophysical Journal 104(8) 1794–1804concentration of active TGF-b to equilibrate throughout
the depth of the tissue (Fig. 6 A). It is highly likely that
the active TGF-b will have been internalized by chondro-
cytes or degraded by proteases well before this state is
reached.
The results of this study complement our previous charac-
terization of mechanical, shear-induced TGF-b activation
(13). Together, these results strongly suggest a sequential
physiologic mechanism through which SZ chondrocytes
obtain access to active TGF-b (Fig. 7). Articular chondro-
cytes (throughout the entire depth of the tissue) and synovio-
cytes constitutively synthesize and secrete large quantities
of latent TGF-b into the SF, producing large stores of
soluble growth factor. Upon physiologic joint motion, SF
is subjected to high levels of mechanical shearing, which
in turn induces the rapid activation of TGF-b (13). As this
newly activated TGF-b diffuses into the cartilage ECM, it
binds and accumulates in the SZ of the tissue to perform
an important functional role. Our previous finding that latent
TGF-b in healthy SF does not undergo spontaneous activa-
tion in the absence of shearing (e.g., via chemical media-
tors) strongly suggests that shear-induced activation is the
dominant physiologic mechanism through which SZ carti-
lage obtains access to active TGF-b.
Furthermore, the observed significant degree of partition-
ing of the SLC (partition coefficient of 0.04–0.05) suggests
that although latent TGF-b can transport into or out of the
tissue, it first must undergo activation in SF before it can
enter the cartilage ECM at substantial levels. This level of
partitioning in cartilage is routinely observed for large
proteins that do not bind to the ECM (32). In the native
synovial joint, latent TGF-b may be present in both the
SLC and LLC (40). Although the LLC in SF may bind to
the cartilage ECM, due to its molecular weight, which is
considerably larger than that of the SLC, it is also unlikely
to enter the tissue from SF at appreciable levels.
Based on the well-characterized influence of TGF-b on
chondrocyte biosynthesis, this mechanism is likely to play
an important role in the metabolic activity of SZ cartilage.
Inhibition of TGF-b signaling promotes cartilage degrada-
tion with effects that are most pronounced in the SZ of the
tissue (41). TGF-b exposure has routinely been shown to
enhance the synthesis of a host of ECM structural proteins,
such as proteoglycans (6,7,42), type II collagen (8), carti-
lage oligomeric matrix protein (COMP) (43), and other
signaling molecules (44). Further, the induction ofted in finite-element theoretical simulations
d rate
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A FIGURE 6 Theoretical simulation of 1D depth-
dependent uptake of exogenous active TGF-b1
(CBath ¼ 10 ng/mL) in a cartilage explant. (A)
Simulations based on binding and transport pro-
perties summarized in Table 2. The solid curve
represents the level of endogenous latent TGF-b1
throughout the depth of the tissue based on
experimental measures (Fig. 2 A). (B) Simulation
of a diffusing 25 kDa molecule in the absence of
binding interactions with a partition coefficient of
k ¼ 0.09. The concentration in the tissue does
not exceed the value of kCBath and reaches a nearly
uniform value throughout the thickness after
only 40 h.
TGF-b Accumulation in Superficial Cartilage 1801chondrocyte biosynthesis by active TGF-b often exhibits
a biphasic concentration-dependent response, suggesting
that the tight regulation of TGF-b activity in SF is crucial
for maintaining cartilage metabolism. Interestingly, for
a variety of proteins (e.g., proteoglycans (7) and SZ protein
(SZP) (45)) maximal induction occurs at the levels of active
TGF-b induced by SF shearing (1–10 ng/mL). In particular,
this mechanism may play a critical role in the regulation of
SZP, a molecule that is secreted exclusively by SZ chondro-
cytes and is believed to reduce friction or wear at the artic-
ular surface of cartilage (46). It is of particular interest to
note that SZ chondrocytes do not synthesize SZP in the
absence of active TGF-b (45,47,48). Therefore, shear-
induced activation may be required for SZP production
and serve as a self-regulating mechanism whereby pro-
longed joint sliding motion can induce a replenishment
mechanism for this tribologically beneficial protein.
Although the importance of TGF-b is clear, its activity
may also play a role in the development and progression
of pathological conditions. High active TGF-b levels have
been shown to induce pathological effects associated with
osteoarthritis, such as inflammation, synovial fibrosis, and
the formation of osteophytes (49–51). Furthermore, high
steady-state levels of active TGF-b have been observed in
pathological SF samples (10,11). Investigators have
questioned whether these growth-factor states contribute
to or counteract pathologic conditions (52,53). Control ofFIGURE 7 Sequential mechanistic illustration of physiologic accumulation o
TGF-b are constitutively synthesized and secreted from the cartilage and synoviu
shearing induced by physiologic joint motion (13). (C) Active TGF-b accumul
nonspecific binding sites in the ECM.TGF-b activation through physiologic joint shearing may
provide the active TGF-b levels required for chondrocyte
metabolic activity while preventing the excessive levels
that are associated with a pathologic response.
It remains unclear which specific ECM molecules are
responsible for the binding of active TGF-b and accumula-
tion in the SZ. Active TGF-b has been demonstrated to bind
to a large variety of ECM molecules, such as the core
protein of proteoglycans (decorin, biglycan, and fibromodu-
lin (20)), glycosaminoglycans (hyaluronan, chondroitin
sulfate, heparin, and heparin sulfate (21,22)), COMP (25),
and possibly type II collagen (23). The specificity of these
interactions may be an additional factor in the role of
TGF-b, since TGF-b’s interactions with protein can stimu-
late or inhibit its activity (54,55). Although activated
TGF-b can physically reassociate with free LAP, given the
low affinity of this interaction and physiologic levels of
these two molecules, appreciable amounts of reassociation
are unlikely to occur (56).
Further, high levels of endogenous latent TGF-b1 are
present in the cartilage ECM, as observed in the absence
of active TGF-b exposure (Fig. 2 A). Although these high
TGF-b levels were previously reported in articular cartilage
(2), to our knowledge, this is the first study to demonstrate
that their concentration is highest at the articular surface
and decreases through the depth of the tissue. Convention-
ally, in a variety of tissues, latent TGF-b is understood tof active TGF-b in the SZ of articular cartilage. (A) Large amounts of latent
m into SF. (B) TGF-b undergoes rapid activation from the high levels of SF
ates in the SZ of the cartilage tissue due to the overwhelming presence of
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1802 Albro et al.bind to the ECM through interactions with proteins, such as
elastin (57), fibrillin (58), and fibronectin, via the LTBP.
Interestingly, these ECM constituents are present at higher
levels in the SZ of the tissue (59–62) and thus may be
responsible for the observed heterogeneous distribution of
latent TGF-b.
An additional implication of this study is that nonspecific
binding interactions make it highly unlikely that a significant
amount of active TGF-b from the SF will reach the middle
and deep zones of the tissue. In spite of this limitation, it has
been clearly demonstrated that TGF-b is required to main-
tain the biochemical integrity of these deeper cartilage
regions (41). Therefore, it is likely that the deeper zones
access active TGF-b from an alternative source, most likely
the large endogenous stores of matrix-bound latent TGF-b
(Fig. 2 A). It has been suggested that cartilage matrix-bound
TGF-b may undergo activation from a variety of chemical
mediators, such as matrix metalloproteinases (63–65),
plasmin (40), transglutaminase (66), and lysophospholipids
(67). Alternatively, the direct mechanical compression that
cartilage experiences during joint motion may activate this
matrix-bound latent TGF-b, akin to the shear-induced acti-
vation of the soluble TGF-b in SF. Future studies will be
required to elucidate the contributions of each of these
potential mechanisms.
Overall, the results of this study provide a novel (to our
knowledge) insight into the likely dominant mechanism
that regulates active TGF-b levels in SZ cartilage. This anal-
ysis can potentially lead to an understanding of the factors
that lead to deviations in TGF-b activity and their potential
role in the progression of pathological conditions of the
synovial joint.SUPPORTING MATERIAL
Supplemental Results and one table are available at http://www.biophysj.
org/biophysj/supplemental/S0006-3495(13)00289-0.
This work was supported by grants R01AR060361 and R01AR43628 from
the National Institute of Arthritis and Musculoskeletal and Skin Diseases.
The content is solely the responsibility of the authors and does not neces-
sarily represent the official views of the National Institute of Arthritis
and Musculoskeletal and Skin Diseases or the National Institutes of Health.REFERENCES
1. Roberts, A. B., and M. B. Sporn. 1988. Transforming growth factor b.
Adv. Cancer Res. 51:107–145.
2. Morales, T. I., M. E. Joyce, ., A. B. Roberts. 1991. Transforming
growth factor-b in calf articular cartilage organ cultures: synthesis
and distribution. Arch. Biochem. Biophys. 288:397–405.
3. Gelb, D. E., R. N. Rosier, and J. E. Puzas. 1990. The production of
transforming growth factor-b by chick growth plate chondrocytes in
short term monolayer culture. Endocrinology. 127:1941–1947.
4. Malemud, C. J. 1993. The role of growth factors in cartilage metabo-
lism. Rheum. Dis. Clin. North Am. 19:569–580.Biophysical Journal 104(8) 1794–18045. Chandrasekhar, S., and A. K. Harvey. 1988. Transforming growth
factor-b is a potent inhibitor of IL-1 induced protease activity and carti-
lage proteoglycan degradation. Biochem. Biophys. Res. Commun.
157:1352–1359.
6. Hiraki, Y., H. Inoue,., F. Suzuki. 1988. Effect of transforming growth
factor b on cell proliferation and glycosaminoglycan synthesis by
rabbit growth-plate chondrocytes in culture. Biochim. Biophys. Acta.
969:91–99.
7. O’Keefe, R. J., J. E. Puzas,., R. N. Rosier. 1988. Effects of transform-
ing growth factor-b on matrix synthesis by chick growth plate chondro-
cytes. Endocrinology. 122:2953–2961.
8. Redini, F., P. Galera,., J. P. Pujol. 1988. Transforming growth factor
b stimulates collagen and glycosaminoglycan biosynthesis in cultured
rabbit articular chondrocytes. FEBS Lett. 234:172–176.
9. Hyytia¨inen, M., C. Penttinen, and J. Keski-Oja. 2004. Latent TGF-b
binding proteins: extracellular matrix association and roles in TGF-b
activation. Crit. Rev. Clin. Lab. Sci. 41:233–264.
10. Fava, R., N. Olsen, ., T. Pincus. 1989. Active and latent forms of
transforming growth factor b activity in synovial effusions. J. Exp.
Med. 169:291–296.
11. Brennan, F. M., D. Chantry,., M. Feldmann. 1990. Detection of trans-
forming growth factor-b in rheumatoid arthritis synovial tissue: lack of
effect on spontaneous cytokine production in joint cell cultures. Clin.
Exp. Immunol. 81:278–285.
12. Miossec, P., M. Naviliat,., J. Banchereau. 1990. Low levels of inter-
leukin-4 and high levels of transforming growth factor b in rheumatoid
synovitis. Arthritis Rheum. 33:1180–1187.
13. Albro, M. B., A. D. Cigan,., G. A. Ateshian. 2012. Shearing of syno-
vial fluid activates latent TGF-b. Osteoarthritis Cartilage. 20:1374–
1382.
14. Lafyatis, R., N. L. Thompson, ., R. L. Wilder. 1989. Transforming
growth factor-b production by synovial tissues from rheumatoid
patients and streptococcal cell wall arthritic rats. Studies on secretion
by synovial fibroblast-like cells and immunohistologic localization.
J. Immunol. 143:1142–1148.
15. Studer, R. K., H. I. Georgescu, ., C. H. Evans. 1999. Inhibition of
transforming growth factor b production by nitric oxide-treated chon-
drocytes: implications for matrix synthesis. Arthritis Rheum. 42:248–
257.
16. Villiger, P. M., andM. Lotz. 1992. Differential expression of TGF b iso-
forms by human articular chondrocytes in response to growth factors.
J. Cell. Physiol. 151:318–325.
17. Lafeber, F. P., P. M. Vander Kraan, ., J. W. Bijlsma. 1993. Osteoar-
thritic human cartilage is more sensitive to transforming growth factor
b than is normal cartilage. Br. J. Rheumatol. 32:281–286.
18. Le, M., C. M. Gohr, and A. K. Rosenthal. 2001. Transglutaminase
participates in the incorporation of latent TGFb into the extracellular
matrix of aging articular chondrocytes. Connect. Tissue Res. 42:
245–253.
19. Rider, C. C. 2006. Heparin/heparan sulphate binding in the TGF-b cyto-
kine superfamily. Biochem. Soc. Trans. 34:458–460.
20. Hildebrand, A., M. Romarı´s,., E. Ruoslahti. 1994. Interaction of the
small interstitial proteoglycans biglycan, decorin and fibromodulin
with transforming growth factor b. Biochem. J. 302:527–534.
21. Hintze, V., A. Miron, ., D. Scharnweber. 2012. Sulfated hyaluronan
and chondroitin sulfate derivatives interact differently with human
transforming growth factor-b1 (TGF-b1). Acta Biomater. 8:2144–
2152.
22. Lyon, M., G. Rushton, and J. T. Gallagher. 1997. The interaction of the
transforming growth factor-bs with heparin/heparan sulfate is isoform-
specific. J. Biol. Chem. 272:18000–18006.
23. Qi, W. N., and S. P. Scully. 1997. Extracellular collagen modulates
the regulation of chondrocytes by transforming growth factor-b 1.
J. Orthop. Res. 15:483–490.
TGF-b Accumulation in Superficial Cartilage 180324. Paralkar, V. M., S. Vukicevic, and A. H. Reddi. 1991. Transforming
growth factor b type 1 binds to collagen IV of basement membrane
matrix: implications for development. Dev. Biol. 143:303–308.
25. Haudenschild, D. R., E. Hong, ., P. E. Di Cesare. 2011. Enhanced
activity of transforming growth factor b1 (TGF-b1) bound to cartilage
oligomeric matrix protein. J. Biol. Chem. 286:43250–43258.
26. Murphy-Ullrich, J. E., S. Schultz-Cherry, and M. Ho¨o¨k. 1992. Trans-
forming growth factor-b complexes with thrombospondin. Mol. Biol.
Cell. 3:181–188.
27. Zhang, L., B. S. Gardiner, ., A. J. Grodzinsky. 2010. On the role of
diffusible binding partners in modulating the transport and concentra-
tion of proteins in tissues. J. Theor. Biol. 263:20–29.
28. Reisenbichler, H., and R. L. Jirtle. 1994. BSA treatment of plasticware
reduces TGF b binding. Biotechniques. 17:675–676.
29. McGowan, K. B., M. S. Kurtis, ., R. L. Sah. 2002. Biochemical
quantification of DNA in human articular and septal cartilage using Pi-
coGreen and Hoechst 33258. Osteoarthritis Cartilage. 10:580–587.
30. Ateshian, G. A., M. B. Albro, ., J. A. Weiss. 2011. Finite element
implementation of mechanochemical phenomena in neutral deform-
able porous media under finite deformation. J. Biomech. Eng.
133:081005.
31. Maas, S. A., B. J. Ellis,., J. A.Weiss. 2012. FEBio: finite elements for
biomechanics. J. Biomech. Eng. 134:011005.
32. Maroudas, A. 1970. Distribution and diffusion of solutes in articular
cartilage. Biophys. J. 10:365–379.
33. Roberts, A. B. 1998. Molecular and cell biology of TGF-b. Miner.
Electrolyte Metab. 24:111–119.
34. Dallas, S. L., S. Park-Snyder,., L. F. Bonewald. 1994. Characteriza-
tion and autoregulation of latent transforming growth factor b (TGF b)
complexes in osteoblast-like cell lines. Production of a latent complex
lacking the latent TGF b-binding protein. J. Biol. Chem. 269:6815–
6821.
35. Bascom, C. C., J. R. Wolfshohl,., H. L. Moses. 1989. Complex regu-
lation of transforming growth factor b 1, b 2, and b 3 mRNA expression
in mouse fibroblasts and keratinocytes by transforming growth factors
b 1 and b 2. Mol. Cell. Biol. 9:5508–5515.
36. Van Obberghen-Schilling, E., N. S. Roche, ., A. B. Roberts. 1988.
Transforming growth factor b 1 positively regulates its own expression
in normal and transformed cells. J. Biol. Chem. 263:7741–7746.
37. Kraus, V. B., T. V. Stabler, ., G. McDaniel. 2007. Measurement of
synovial fluid volume using urea. Osteoarthritis Cartilage. 15:1217–
1220.
38. Faber, S. C., F. Eckstein, ., M. Reiser. 2001. Gender differences in
knee joint cartilage thickness, volume and articular surface areas:
assessment with quantitative three-dimensional MR imaging. Skeletal
Radiol. 30:144–150.
39. Garcia, A. M., N. Szasz,., E. H. Frank. 2003. Transport and binding
of insulin-like growth factor I through articular cartilage. Arch. Bio-
chem. Biophys. 415:69–79.
40. Pedrozo, H. A., Z. Schwartz,., B. D. Boyan. 1999. Potential mecha-
nisms for the plasmin-mediated release and activation of latent trans-
forming growth factor-b1 from the extracellular matrix of growth
plate chondrocytes. Endocrinology. 140:5806–5816.
41. Chen, C. G., D. Thuillier,., T. Alliston. 2012. Chondrocyte-intrinsic
Smad3 represses Runx2-inducible matrix metalloproteinase 13 expres-
sion to maintain articular cartilage and prevent osteoarthritis. Arthritis
Rheum. 64:3278–3289.
42. Morales, T. I., and A. B. Roberts. 1988. Transforming growth factor
b regulates the metabolism of proteoglycans in bovine cartilage organ
cultures. J. Biol. Chem. 263:12828–12831.
43. Recklies, A. D., L. Baillargeon, and C. White. 1998. Regulation of
cartilage oligomeric matrix protein synthesis in human synovial cells
and articular chondrocytes. Arthritis Rheum. 41:997–1006.
44. Shi, S., S. Mercer,., S. B. Trippel. 2009. Growth factor regulation of
growth factors in articular chondrocytes. J. Biol. Chem. 284:6697–
6704.45. Niikura, T., and A. H. Reddi. 2007. Differential regulation of lubricin/
superficial zone protein by transforming growth factor b/bone morpho-
genetic protein superfamily members in articular chondrocytes and
synoviocytes. Arthritis Rheum. 56:2312–2321.
46. Swann, D. A., S. Sotman,., C. Brooks. 1977. The isolation and partial
characterization of the major glycoprotein (LGP-I) from the articular
lubricating fraction from bovine synovial fluid. Biochem. J. 161:
473–485.
47. Schmidt, T. A., N. S. Gastelum,., R. L. Sah. 2008. Differential regu-
lation of proteoglycan 4 metabolism in cartilage by IL-1a, IGF-I, and
TGF-b1. Osteoarthritis Cartilage. 16:90–97.
48. Neu, C. P., A. Khalafi,., A. H. Reddi. 2007. Mechanotransduction of
bovine articular cartilage superficial zone protein by transforming
growth factor b signaling. Arthritis Rheum. 56:3706–3714.
49. van Beuningen, H. M., P. M. van der Kraan, ., W. B. van den Berg.
1994. Transforming growth factor-b 1 stimulates articular chondrocyte
proteoglycan synthesis and induces osteophyte formation in the murine
knee joint. Lab. Invest. 71:279–290.
50. Elford, P. R., M. Graeber, ., A. R. MacKenzie. 1992. Induction of
swelling, synovial hyperplasia and cartilage proteoglycan loss upon
intra-articular injection of transforming growth factor b-2 in the rabbit.
Cytokine. 4:232–238.
51. Allen, J. B., C. L. Manthey,., S. M. Wahl. 1990. Rapid onset synovial
inflammation and hyperplasia induced by transforming growth factor
b. J. Exp. Med. 171:231–247.
52. Westacott, C. I., and M. Sharif. 1996. Cytokines in osteoarthritis: medi-
ators or markers of joint destruction? Semin. Arthritis Rheum. 25:254–
272.
53. van den Berg, W. B. 1995. Growth factors in experimental osteoar-
thritis: transforming growth factor b pathogenic? J. Rheumatol. Suppl.
43:143–145.
54. Takeuchi, Y., Y. Kodama, and T. Matsumoto. 1994. Bone matrix de-
corin binds transforming growth factor-b and enhances its bioactivity.
J. Biol. Chem. 269:32634–32638.
55. Hausser, H., A. Gro¨ning, ., H. Kresse. 1994. Selective inactivity of
TGF-b/decorin complexes. FEBS Lett. 353:243–245.
56. Bo¨ttinger, E. P., V. M. Factor,., M. B. Sporn. 1996. The recombinant
proregion of transforming growth factor b1 (latency-associated
peptide) inhibits active transforming growth factor b1 in transgenic
mice. Proc. Natl. Acad. Sci. USA. 93:5877–5882.
57. Karonen, T., L. Jeskanen, and J. Keski-Oja. 1997. Transforming growth
factor b 1 and its latent form binding protein-1 associate with elastic
fibres in human dermis: accumulation in actinic damage and absence
in anetoderma. Br. J. Dermatol. 137:51–58.
58. Raghunath, M., C. Unso¨ld,., M. Meuli. 1998. The cutaneous micro-
fibrillar apparatus contains latent transforming growth factor-b binding
protein-1 (LTBP-1) and is a repository for latent TGF-b1. J. Invest.
Dermatol. 111:559–564.
59. Yu, J., and J. P. Urban. 2010. The elastic network of articular cartilage:
an immunohistochemical study of elastin fibres and microfibrils.
J. Anat. 216:533–541.
60. Mansfield, J., J. Yu,., P. Winlove. 2009. The elastin network: its rela-
tionship with collagen and cells in articular cartilage as visualized by
multiphoton microscopy. J. Anat. 215:682–691.
61. Yeh, A. T., M. J. Hammer-Wilson, ., G. M. Peavy. 2005. Nonlinear
optical microscopy of articular cartilage. Osteoarthritis Cartilage.
13:345–352.
62. Balazs, E. A. 2009. The role of hyaluronan in the structure and function
of the biomatrix of connective tissues. Struct. Chem. 20:233–243.
63. Maeda, S., D. D. Dean, ., B. D. Boyan. 2002. The first stage of
transforming growth factor b1 activation is release of the large
latent complex from the extracellular matrix of growth plate chondro-
cytes by matrix vesicle stromelysin-1 (MMP-3). Calcif. Tissue Int.
70:54–65.Biophysical Journal 104(8) 1794–1804
1804 Albro et al.64. Dangelo, M., D. P. Sarment,., M. Pacifici. 2001. Activation of trans-
forming growth factor b in chondrocytes undergoing endochondral
ossification. J. Bone Miner. Res. 16:2339–2347.
65. Maeda, S., D. D. Dean, ., B. D. Boyan. 2001. Activation of latent
transforming growth factor b1 by stromelysin 1 in extracts of growth
plate chondrocyte-derived matrix vesicles. J. Bone Miner. Res.
16:1281–1290.Biophysical Journal 104(8) 1794–180466. Rosenthal, A. K., C. M. Gohr, ., M. Le. 2000. Participation of
transglutaminase in the activation of latent transforming growth
factor b1 in aging articular cartilage. Arthritis Rheum. 43:1729–
1733.
67. Gay, I., Z. Schwartz, ., B. D. Boyan. 2004. Lysophospholipid regu-
lates release and activation of latent TGF-b1 from chondrocyte extra-
cellular matrix. Biochim. Biophys. Acta. 1684:18–28.
